A new AI model to improve trial enrollment, importing drugs from Canada, and more biotech news from The Readout
Adobe
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Let’s get straight to the news today.
The need-to-know this morning
Moderna said Ester Banque joined the company as chief commercial officer. She was formerly president of U.S. operations for Zoetis. Moderna President Stephen Hoge has also been given an expanded role overseeing several of the company’s drug development programs.
New AI model aims to improve trial enrollment
The biotech Verge Labs today released a new AI model that it says will help determine which patients will respond to treatment better, leading to fewer people dropping out while also increasing the statistical power of a trial.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaineywchen.70.
Read the full article at STAT News →📄Source document: Moderna Appoints New Chief Commercial Officer
3 reports
STAT NewsIndependentCenter5 days agoThe article discusses recent developments in the biotechnology sector, including Moderna appointing a new chief commercial officer and the launch of a new AI model by Verge Labs aimed at improving clinical trial enrollment. The article also mentions other biotech news such as the impact of FDA changes on companies and advancements in obesity treatments.
Bias read (Center): The article focuses on business and technological developments within the biotechnology industry without taking a stance on any political issue. It provides factual updates on corporate appointments and innovations without editorializing or biased language.
Official sources cited
- organisation Moderna Appoints New Chief Commercial Officer
- organisation Verge Labs Launches New AI Model
STAT NewsIndependentCenter5 days ago STAT+: Verge Labs’ new AI model solves patient stratification problems for neurology clinical trialsVerge Labs, a biotechnology company founded by Alice Zhang, developed an AI model aimed at improving patient stratification for neurology clinical trials. The company previously focused on identifying genetic networks linked to neurodegenerative diseases such as Parkinson’s, ALS, and Alzheimer’s. While Verge Genomics identified promising drug targets, including two selected by Eli Lilly for their pipeline, its recent Phase 1b trial for an ALS drug failed due to high patient dropout rates caused by intolerance to the treatment. The company has shared insights from this failure to benefit future
Bias read (Center): The article provides a factual overview of Verge Labs' research efforts, clinical trial outcomes, and subsequent analysis without overtly favoring any particular perspective. It focuses on technical details and does not include subjective commentary or biased language.
Official sources cited
- organisation Verge Labs Postmortem Analysis of Phase 1b Trial Failure
VoxIndependentCenter9 days agoThis article discusses the potential intersection between artificial intelligence safety concerns and genetic engineering, suggesting that future debates around AI might involve ethical and technical considerations related to DNA manipulation.
Bias read (Center): The article does not exhibit clear ideological framing, focusing instead on the technical and ethical implications of combining AI with genetic engineering without taking a stance on either side.
United States